Table 1 Characteristics of patients with GT3-HCV infection who received a sofosbuvir containing treatment regime

Sample size

102

57

24

21

Age

39.99 (38.22–41.76)

39.16 (36.83–41.48)

44.25 (40.8–47.70)

37.38 (33.10–41.67)

Gender (M/F)

62/40

28/29

20/4

13/8

Route of Infection

(Travenous drug abuse/Blood products/Others)

58/18/26

34/7/16

10/6/8

14/5/2

Cirrhosis(yes/no)

33/69

4/53

24/0

5/16

Baseline HCV RNA (log10 IU/ml)

6.23 (6.04–6.43)

6.26 (5.99–6.54)

6.33 (5.94–6.73)

6.04 (5.60–6.48)

Baseline ALT (IU/mL)

95.70 (78.88–112.51)

102.67 (78.10–127.24)

112.68 (78.89–146.47)

57.37 (30.01–84.72)

Baseline AST (IU/mL)

81.96 (72.12–91.80)

91.33 (77.48–105.19)

89.86 (71.20–108.52)

47.50 (31.63–63.36)

Baseline TBil (μmol/mL)

19.95 (18.57–21.32)

18.91 (17.22–20.59)

22.01 (18.07–25.94)

20.42 (18.07–22.77)

Baseline PLT (10⁹/L)

142.94 (129.36–156.52)

157.65 (139.05–176.25)

104.96 (79.71–130.21)

146.43 (117.94–174.91)

Baseline FIB-4

4.03 (2.99–5.07)

3.75 (2.27–5.23)

5.70 (3.81–7.58)

2.86 (0.52–5.19)

Baseline APRI

2.15 (1.66–2.64)

2.07 (1.40–2.74)

3.11 (2.02–4.20)

1.26 (0.36–2.16)